Remicade/Remicade Biosimilars Enrollment Form



Fax Referral To: 1-866-843-3221 Phone: 1-866-899-1661 Email Referral To: DL-NCCNEWREFERRAL@cvshealth.com



		Six Simple Steps to Sub	mitting a Referra				
PATIENT IN	IFORMATION (Cor	mplete or include demographic	sheet)				
Patient Name:	·		DOB:	Geno	der: 🗌 Male	☐ Female	
Address:							
		e (to primary # provided below)	Text (to cell # p	provided below)	Email (to ema	ail provided	
below)							
		ing the phone number(s) and email					
		about your prescription(s), accoun		ndard data rates appl	y. Message free	quency varies.	
		alty Pharmacy will attempt to contac					
	mail: Primary Language: Last Four of SSN: Primary Language: arent/Caregiver/Legal Guardian Name (Last, First): Relationship to patient :						
Parent/Caregive	ər/Legal Guardian Nar	ne (Last, First):	Relationship	to patient:			
-		_					
	ER INFORMATION						
) #:			
		Group or Hospital:					
Address:		City, Sta	te, ZIP Code:				
Phone:	Fax:	Contact Pers	son:	Contact's F	² hone:		
3 INSURANC	EINFORMATION	Please fax copy of prescription	n and insurance car	ds with this form, if	available (fro	ont and back)	
Is the Patient Ins	sured? □Yes □ No	Is the Patient enrolled or eligi	ble for Medicare/M	ledicaid? □Yes □	1 No	,	
		Policy H					
		Telephone:					
Prescription Insu	urance:		Prescription F	Plan Telephone:	, c c c. c t		
Policy ID:		Group #:	RX BIN #:	RX I	PCN #:		
•		nanufacturer copay assistance					
_ ,		, ,	, , , ,				
DIAGNOSIS	S AND CLINICAL	INFORMATION					
_		IN ORMATION					
Diagnosis (ICD-	n's disease (CD) of the	s small intestine	K51.90 Ulcerati	ivo colitic (LIC)			
L40.0 Plaque		e small intestine		pathic psoriasis (Ps/	۸۱		
	•			•	•		
	matoid arthritis (RA)		☐ M45.9 Ankylos	ing spondylitis (AS)	1		
Uther Code:	Description _				——		
		NKDA Weight:_)	in	∐ cm	
Prior therapy, tre	eatment dates, and rea	ason(s) for discontinuation:					
reatment status	s:	Continuation of therapy; da	te of last treatment	// Need	is by date:		
Nursing and A	<u> Administration:</u>						
First dose admin	nistration of monoclon	al antibodies (mABs) should be	administered in a c	controlled setting (r	nay vary depe	ending upon	
medication spec	cific policy).			•			
-		s, the first dose must be admir	istered in a contro	olled setting.			
		ne health Infusion nurse visit as					
· · · · · · · · · · · · · · · · · · ·		Coram Ambulatory Infusion Su			Other Infusi	ion Clinic	
		Flushes, Supplies, Nursing Ser					
		linic: Drug only for facility adm	•				

Remicade/Remicade Biosimilars Enrollment Form

	P	ease Complete Patient, Prescriber and Patient Cli	nical Information			
Patient Name:		Patient DOB: Patient Phone:				
Patient Address: _						
Prescriber Name: .		Prescribe	er Phone:			
<u>Patient Clinical In</u>	<u>formation:</u>	_				
Allergies:	b 🗌 kg Height: 🔲 in 🗌 cm					
		d reason(s) for discontinuation:				
		py \square Continuation of therapy; date of last treatmen	t/ Needs by date:			
		ON Ship to: Patient Office Other:				
MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILL			
		AS Induction Dose:	Quantity: (# of vials			
		Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2,	6 and every Refills: 0			
		6 weeks thereafter				
		AS Maintenance Dose:	Quantity: (# of vials			
		Infuse IV at 5 mg/kg (Dose =mg) every 6 weeks	Refills:			
☐ Avsola		☐ CD (Adult and Pediatric ≥ 6 years old) Induction D				
		Infuse IV at 5 mg/kg (Dose =mg) at weeks 0	, 2, 6 and every Refills: 0			
_		8 weeks thereafter	0 /// 6			
☐ Inflectra		CD (Adult) Maintenance Dose:	Quantity: (# of vials			
		Infuse IV at 5-10 mg/kg (Dose =mg) every 8				
☐ Infliximab		☐ CD (Pediatric ≥ 6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 we	Quantity: (# of vials			
Піннхіттар	100 mg vial	PsO/PsA Induction Dose:	eks Refills: (# of vials			
		Infuse IV at 5 mg/kg (Dose =mg) at weeks 0				
Remicade		8 weeks thereafter	, z, o and every Rentis. O			
Remidade		PsO/PsA Maintenance Dose:	Quantity: (# of vials			
		Infuse IV at 5 mg/kg (Dose =mg) every 8 we				
Renflexis		RA Induction Dose:	Quantity: (# of vials			
_		Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2				
		8 weeks thereafter				
		RA Maintenance Dose:	Quantity: (# of vials			
		Infuse IV at 3-10 mg/kg (Dose =mg) every 4				
		(circle one)				
		☐ UC (Adult and Pediatric ≥ 6 years old) Induction D	ose: Quantity: (# of vials			
		Infuse IV at 5 mg/kg (Dose =mg) at weeks 0	, 2, 6 and every Refills: 0			
		8 weeks thereafter				
		☐ UC (Adult and Pediatric ≥ 6 years old) Maintenand				
		Infuse IV at 5 mg/kg (Dose =mg) every 8 we	eks Refills:			
Other:			Quantity: (# of vials			
	-		Refills:			
PRESCRIRE	R SIGNATI IDI	REQUIRED (STAMP SIGNATURE NOT AL	I OWFD)			
			oduct Selection Permitted /			
DAW / May Not Subst	titute	Substitution Permis				
Prescriber's Sig	nature:	Date: Prescriber's S	ignature:Date:			

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Remicade/Remicade Biosimilars Enrollment Form Nursing Orders

			and Patient Clinical Information	
			Patient Phone: _	
Patient Address:				
Prescriber Name:			Prescriber Phone:	
5 PRESCRIPTION IN	FORMATIO	${f N}$ **ITEMS BELOW THIS LINE W	ILL ONLY BE SENT FOR INFUSIONS DO	NE AT HOME/CORAM AIS**
MEDICATION/SUPPLIES	ROUTE	DOSE /STRE	NGTH/ DIRECTIONS	QUANTITY/REFILLS
Catheter: PIV PORT CVC/PICC	IV	maintain IV access and patend PIV: NS 5 mL (Heparin 10 units	or/mL 3-5 mL if multiple days) parin 10 units/mL or ☐ 100 units/mL ccess PORT w/ huber needle	Quantity: Refills:
Hydration: ☐ NS ☐ D5W	IV	Pre:	00 mL	Hydration max infusion rate mL/hr (Adult max rate 250 mL/hr unless otherwise indicated)
☐Epinephrine **nursing requires**	□ IM □ SC	☐ 1:2000, 0.15mg/0.3 mL (15- ☐ 1:1000, 0.1 mg/kg, Max 0.3 Mild-Moderate Reactions. Ma for severe allergic reaction, als	1000, 0.3mg/0.3 mL (greater than 30 kg/66 lbs) 2000, 0.15mg/0.3 mL (15-30 kg/33-66 lbs) 1000, 0.1 mg/kg, Max 0.3mg (under 15kg) Moderate Reactions. May repeat in 3-5 minutes as needed evere allergic reaction, also call 911	
☐ Diphenhydramine Oral	РО	Premedication: ☐ 12.5 mg/kg (0-30 kg) ☐ 25 mg ☐ 50 mg (Over 30 kg)		Quantity: Refills:
Diphenhydramine 50 mg/mL vial **nursing required**	Slow IV	1 mg/kg (under 15 kg) 12.5 mg-50 mg (15-30 kg) 25 mg-50 mg (Over 30 kg) If mild/moderate reaction: may repeat in 3-5 minutes as needed (Adult max dose: 100 mg/day) If severe allergic reaction: call 911		Quantity: Refills:
☐ Flush Orders:	Peripheral Access Central Venous Access	☐ 10 mL NS post flush ☐ 50 mL NS post flush to clear medication from tubing (recommended if no post-hydration)☐ Other:		Send quantity sufficient for medication days supply
Additional Medication:				
□ Patient is interested in patient supp PRESCRIBER SIGN		STAMP SIGNATURE NOT ALLOWED OUTPED (STAMP SIGNAT		provided as needed for administration
"Dispense As Written" / Brand M DAW / May Not Substitute Prescriber's Signature:	edically Necessary /	Do Not Substitute / No Substitution / Date:	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	Date:
CA MA NC & PP: Interchance is r	nandated unless Pros	criber writes the words " No Substitution "	ATTN: New York and lowa provide	rs, please submit electronic prescription
The state of the s	nandated diliess Fiest		AT IN. NOW FOR All a lowa provide	picase subititi electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.